Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Verekitug

Copy Product Info
😃Good
Catalog No. T9901A-507Cas No. 2768386-15-6

Verekitug is a novel, recombinant, fully human monoclonal antibody developed to selectively target thymic stromal lymphopoietin receptor (TSLPR) with high potency. Verekitug is currently being investigated as a potential therapeutic candidate for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), where overactivation of TSLPR contributes to disease pathology. Verekitug offers a promising approach to immune modulation in respiratory and inflammatory disease research.

Verekitug

Verekitug

Copy Product Info
😃Good
Purity: 95%
Catalog No. T9901A-507Cas No. 2768386-15-6
Verekitug is a novel, recombinant, fully human monoclonal antibody developed to selectively target thymic stromal lymphopoietin receptor (TSLPR) with high potency. Verekitug is currently being investigated as a potential therapeutic candidate for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), where overactivation of TSLPR contributes to disease pathology. Verekitug offers a promising approach to immune modulation in respiratory and inflammatory disease research.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$198-In Stock
5 mg$645-In Stock
10 mg$987-In Stock
25 mg$1,460-In Stock
50 mg$1,970-In Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:98.1% (SDS-PAGE); 98.9% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information

Product Introduction

Bioactivity
Description
Verekitug is a novel, recombinant, fully human monoclonal antibody developed to selectively target thymic stromal lymphopoietin receptor (TSLPR) with high potency. Verekitug is currently being investigated as a potential therapeutic candidate for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), where overactivation of TSLPR contributes to disease pathology. Verekitug offers a promising approach to immune modulation in respiratory and inflammatory disease research.
Reactivity
Human
Application
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Gene ID
Uniprot ID
TargetCRLF2
Chemical Properties
Molecular Weight144.05 kDa
Cas No.2768386-15-6
Antibody Information
IsotypeHuman IgG1 kappa
Recommended Isotype Control
Storage & Solubility Information
Storagestore at low temperature | -20°C for 1 year | Shipping with blue ice.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator
Related Tags: buy Verekitug | purchase Verekitug | Verekitug cost | order Verekitug | Verekitug molecular weight